ODDIFACT
June 17, 2025
Company Presentation
Orphan and Rare Disease
153C
Established in 2024, ODDIFACT is a ‘‘TechDev’’ AI native company specialized in the repositioning of biologics for rare diseases through the submission of Orphan Drug Designation, turning off-label usages into approved treatments.
We provide new fast-go-to-patients biologic drugs.
We plan to allow pharmaceutical companies to commercialize 50 new rare disease treatments by 2030.
We aim to give access to 500,000 cumulated people to a treatment in 2030.
Thanks to its AI-powered tools, the company has already submitted and obtained 4 Orphan Drug Designations from the FDA and is sustaining a pace of one submission per month as part of its 2025 strategy.
Company HQ City:
Paris
Company HQ State:
FRANCE
Company HQ Country:
France
Year Founded:
03/2024
Lead Product in Development:
Bevacizumab (anti-VEGF) for the treatment of Recurrent Respiratory Papillomatosis (RRP) classified a rare disease
CEO
Pierre-Alexandre TEULIE
Development Phase of Lead Product
Other/Not Applicable
What is your next catalyst (value inflection) update?
June 2025 (fund raising)
Website
https://www.oddifact.com/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}